Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy

J Clin Endocrinol Metab. 2003 Nov;88(11):5150-7. doi: 10.1210/jc.2003-030262.

Abstract

The stable somatostatin analog octreotide has been successfully used for imaging and treatment of a variety of human tumors. In pheochromocytoma, data on somatostatin receptor subtyping have thus far been sparse. Pheochromocytomas often express more than one somatostatin receptor, and it is uncertain by which receptor subtype the functional responses of octreotide are mediated. Here, we have examined somatostatin receptor protein expression in a panel of 52 pheochromocytomas from 35 randomly selected patients by immunostaining with specific polyclonal anti-sst(1-5) and monoclonal mouse anti-SS-14 antibodies. Staining pattern, distribution and subcellular localization of somatostatin receptor subtypes were investigated. Seventeen patients received (111)In-octreotide scintigraphy. Although the vast majority of tumors (90%) showed positive immunohistochemical staining for sst(3), immunoreactive sst(2A) receptors were only seen in 13 tumors (25%). All other somatostatin receptor subtypes were less frequently detected. Interestingly, among sst(3)-positive tumors strikingly different subcellular distributions of immunoreactive sst(3) receptors were observed. In most cases, immunoreactive sst(3) receptors were distributed throughout the cytosol. Scintigraphic localization of tumors larger than 1 cm in diameter was always successful in the presence of immunoreactive sst(2A) receptors. In the absence of sst(2A), true-positive octreotide scintigraphy was only seen in the presence of membrane-associated sst(3) immunoreactivity. Our findings suggest that selective expression of functional membrane-associated sst(3) receptors is sufficient for high tracer uptake during octreotide scintigraphy in a subgroup of human pheochromocytomas. These tumors may represent a potential target treatment with somatostatin receptor agonists with improved sst(3) activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Gland Neoplasms / diagnostic imaging*
  • Adrenal Gland Neoplasms / pathology
  • Antibody Specificity
  • Evaluation Studies as Topic
  • Humans
  • Immunohistochemistry
  • Indium Radioisotopes
  • Membrane Proteins
  • Octreotide
  • Pheochromocytoma / diagnostic imaging*
  • Pheochromocytoma / pathology
  • Radionuclide Imaging
  • Random Allocation
  • Receptors, Somatostatin / immunology
  • Receptors, Somatostatin / metabolism*

Substances

  • Indium Radioisotopes
  • Membrane Proteins
  • Receptors, Somatostatin
  • somatostatin receptor 3
  • somatostatin receptor sst2A
  • somatostatin receptor subtype-4
  • somatostatin receptor type 1
  • somatostatin receptor 5
  • Octreotide